Glutamate agonists for schizophrenia stimulate dopamine D2High receptors.
Seeman
Philip
P
D000596:Amino Acids / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000494:pharmacology; D003499:Cyclic S-Oxides / Q000494:pharmacology; D018491:Dopamine Agonists / Q000494:pharmacology*; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology*; D006801:Humans; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D012559:Schizophrenia / Q000503:physiopathology*
C517803:4-aminho-2-thiabicyclo(3.1.0)hexane-4,6-dicarboxylic acid; D000596:Amino Acids; D014150:Antipsychotic Agents; D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D003499:Cyclic S-Oxides; D018491:Dopamine Agonists; D018690:Excitatory Amino Acid Agonists; C118218:LY 379268; D017448:Receptors, Dopamine D2; C104753:eglumetad